Research conducted by Huve Pharma found understanding of the animal gut is growing, and the link between gut health and superior technical results has become undeniable. A healthy gut and balanced microbiota are rightly seen as the driver of animal growth performance. As such, effective gut management has become increasingly important as animal production continues to aim for more efficiency and productivity.
The research comprised a good example is Bacillus licheniformis DSM 28710 (B-Act®), a spore-forming probiotic with a long and extensive history in animal production. The probiotic’s mode of action is based on the principle of competitive exclusion, including outcompeting undesirable bacteria in terms of nutrients and space, as well as producing potent antimicrobial metabolites with a strong affinity for undesirable bacteria such as Clostridium perfringens. As a result, the composition and balance of the gut microbiota are positively impacted, whilst gut integrity is maintained.
By incorporating B-Act® (A probiotic by Huve Pharma) in the diet from start to finish, it is possible to mitigate gut health challenges during all production stages.
Recent efficacy research focused on the use of B-Act® in layers, showing improvements in both egg quality and egg production. For example, when B-Act® was introduced to Hy-Line Brown layers at a dosage of 500 g/mton (1.6 x 1012 CFU/mton of feed) from 21 to 45 weeks of age, egg production increased significantly whilst feed conversion efficiency improved numerically.
These results were replicated in a second trial with Isa Brown hens from 22 to 34 weeks of age using the same B-Act® dosage. The birds that received B-Act® showed a significantly improved feed conversion efficiency.
Supporting a healthy gut leads to productive and profitable poultry. With an attractive return on investment, B-Act® offers an interesting solution to do so, combining economics with health standards in the most rewarding way.